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Abstract
Background: Steroid action is mediated, in addition to classical intracellular receptors, by recently
identified membrane sites, that generate rapid non-genomic effects. We have recently identified a
membrane androgen receptor site on prostate carcinoma cells, mediating testosterone rapid
effects on the cytoskeleton and secretion within minutes.
Methods: The aim of this study was to investigate whether membrane androgen receptors are
differentially expressed in prostate carcinomas, and their relationship to the tumor grade. We
examined the expression of membrane androgen receptors in archival material of 109 prostate
carcinomas and 103 benign prostate hyperplasias, using fluorescein-labeled BSA-coupled
testosterone.
Results: We report that membrane androgen receptors are preferentially expressed in prostate
carcinomas, and they correlate to their grade using the Gleason's microscopic grading score
system.
Conclusion: We conclude that membrane androgen receptors may represent an index of tumor
aggressiveness and possibly specific targets for new therapeutic regimens.
Background
The biological activity of androgen occurs predominantly
through binding to an intracellular androgen receptor
(iAR) protein, a member of the nuclear receptor super-
family, functioning as a ligand-activated transcription fac-
tor [1]. However, in recent years, a number of reports
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indicate additional rapid androgen actions, including the
rapid activation of kinase-signaling cascades, modifica-
tion of actin cytoskeleton and modulation of intracellular
calcium levels [see [2,3], for reviews]. These actions are
considered to be non-genomic in nature because they
occur in cells lacking functional iARs in the presence of
inhibitors of transcription and translation, or are
observed too rapidly to involve changes in gene transcrip-
tion [4].
We have previously identified membrane androgen recep-
tor (mAR) sites in prostate and breast cancer cell lines [5-
7]. In a preliminary work performed on freshly prepared
epithelial cells from prostate carcinoma, non-cancerous
peritumoral tissue, and benign prostate hyperplasia
(BPH), we have shown that mARs are expressed preferen-
tially on carcinoma cells [8]. Activation of mARs induces
actin cytoskeleton polymerization and redistribution
[5,9], secretion of Prostate Specific Antigen (PSA) and
apoptosis [6,7]. Membrane androgen receptor sites were
responsible for the induction of testosterone-BSA-induced
apoptosis in T47D breast cancer cells [7]. It is interesting
to note that mARs may be different from iARs, as they are
not recognized by antibodies against the latter [5], and are
not inhibited by a series of commonly used antiandrogens
in vitro [9] or in vivo [6].
In the present work we developed a method for the in situ
detection of mARs in formalin-fixed and paraffin-embed-
ded tissues. The aim of the present study was to: (1) Vali-
date a method for the detection of mARs in formalin-fixed
paraffin-embedded specimens of prostate tumors, and (2)
explore the distribution of mARs in prostate carcinomas.
More specifically, we have tried to reply to the following
questions: (a) Are mARs equally distributed in cases of
prostate carcinoma and BPH, and (b) are mARs expressed
in prostate carcinoma related to the gravity of the disease,
as expressed by the Gleason's score?
Methods
One hundred and nine (109) cases of prostate carcinoma
(age 45–93 years, mean ± SD 71.17 ± 9.02, median 71
years, followed for 4 to 72 months) and one hundred and
three (103) cases of BPH (age 37–92, mean ± SD 70.44 ±
8.38, median 70 years), retrieved from the archives of the
Pathology Department of the University Hospital of
Crete, were analyzed retrospectively. Prostate carcinoma
specimens corresponded to 23 radical prostatectomies, 15
transurethral resections harboring incidentally encoun-
tered carcinoma, and 71 transrectal biopsies. Three cases
of carcinoma diagnosed in transurethral resection speci-
mens were rejected for technical reasons. Survival of
patients ranged from 1–72 months (mean ± SD 31.4 ±
9.32, median 29.5 months). Benign prostate hyperplasia
cases corresponded to 96 transurethral resection and 7
prostatectomy specimens. Hematoxylin and Eosin (H&E)
stained slides were reviewed by two investigators inde-
pendently and blindly to the patients' clinical data. The
Gleason's sum (combined score, Gleason's score) [10,11]
of carcinoma cases was reevaluated by two observers. The
results obtained from the histological study of carcinomas
using the Gleason's grading system are presented in Table
1. In case of discrepancy between the two observers, the
final decision was reached by consensus.
A set of three serial, 3 µm thick, tissue sections, embedded
in Paramat extra (BDH Lab Supplies, Poole, UK), were
taken on negatively charged slides (SuperFrost Plus, Kin-
dler O GmbH, Freiburg, Germany) from each representa-
tive paraffin block. Two of the slides were used for the
needs of mAR detection, while the third was stained with
H&E for morphological study, and for grading in the case
of carcinomas.
In order to evaluate the presence of mAR in tissue sec-
tions, we had to (partially) regenerate membrane pro-
teins. In this aim, in an initial set of experiments, we have
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assayed different combinations of melting temperatures
and times of incubation. Our findings indicated that the
optimal conditions for the identification of the highest
specific binding on the target molecules (mARs) were
achieved by mild melting of the embedding medium
(Paramat extra) at 42.5°C for 20 min, followed by dewax-
ing in xylene (three times, 10 min. each) and rehydration
in decreasing concentrations of ethanol. Then, specimens
were washed in distilled water for 20 min. and incubated
at 37°C in a citrate buffer 0.01 M (pH 6.2) for two hours.
Finally, they were washed in Tris Buffered Saline (TBS, 10
mM, NaCl 150 mM, pH 7.4) and processed for the detec-
tion of mARs. As in the present study we used albumin-
conjugated steroids, and in order to minimize the non-
specific binding of BSA we pre-incubated slides with 3%
BSA for 40 min. Then the slides were washed in TBS and
one of them (test slide) was incubated for 1 hour with 10-
6 M Testosterone-BSA-FITC while the other (control slide)
with 10-6 M BSA-FITC (both reagents were obtained from
Sigma, St Louis, MO) in TBS.
Another potential source of non-specific staining could be
the association of the ligand (testosterone) with iARs, due
to the fact that microscopic tissue sections contain broken
(sectioned) cells. Since our previous experiments have
shown that classical antiandrogens react with iARs but not
with mARs [6,9], we routinely used cyproterone acetate (a
specific androgen receptor antagonist, Sigma, St Louis,
MO) at a concentration of 10-4 M, diluted in the testoster-
one-BSA-FITC or BSA-FITC solution in order to block iARs
(see Results). After one-hour incubation, slides were
rinsed with TBS, coverslipped using Polyvinyl Alcohol
Mounting Medium with Dabco Antifading (Fluka Bio-
chemika) and examined under a fluorescence microscope.
An introductory comparative study using both a confocal
laser scanning microscope (Leica TCS SP) and a fluores-
cence microscope (Nikon Microphot-FXA fluorescence
microscope, mounted with a Nikon DX-DB2 photo-
graphic camera) showed no significant advantage of the
confocal over the conventional fluorescence microscope.
The latter was therefore used for the routine detection of
mARs. Results were expressed as a percentage of mAR pos-
itive cells in reference to total number of cells examined in
10 sequential high power fields (X400) in a representative
area of each test slide. The localization and pattern of
staining were recorded.
Clinical data, namely age, previous treatment, follow-up
and survival, were retrieved from the patients' files. Statis-
tical analysis was performed by the Systat V 10.0 (SPSS,
Chicago, IL) program. In the case of positive/negative
cases of BPH and prostate carcinoma, we have used signif-
icance limits of the four-fold table test, using the χ2 test,
with 1 degree of freedom. The same test was used for the
comparison of positive and negative cases in each group.
For exploring the correlation between positive/negative
cases of mAR expression and other parameters (age, treat-
ment, survival, Gleason's sum) the Spearman rank corre-
lation coefficient was calculated. The Mann-Whitney U
test was used to compare the distribution of continuously-
scaled outcomes by mAR expression. All statistical evalua-
tions were double-sided.
This study was approved by the Ethics Committee of the
University Hospital of Heraklion, and the Ethics Commit-
tee of the University of Crete.
Results
1. Validation of the method
Previous results indicated that mARs can be detected in
freshly prepared prostate carcinoma tissue [8]. The
method presented here for the in situ detection of mARs is
based on the binding of a ligand (FITC-BSA-bound testo-
sterone) on mARs. Membrane androgen receptors are
membrane proteins [5,12], expected to be (partially)
denatured in microscopic tissue sections by formalin fixa-
tion, paraffin embedding and high temperatures, condi-
tions known to modify integral membrane proteins.
Therefore, we attempted to renaturate these proteins by
incubating the tissue sections at relatively low tempera-
tures during deparaffinization and renaturation process
(mild tissue dewaxing and protein renaturation). Differ-
ent combinations of melting temperatures (from 40° to
60°C), incubation times, xylene treatment and acidifica-
tion were tried. As indicated in the Methods section, the
best results were obtained with a mild paraffin melting
and protein renaturing temperature of 42.5°C, followed
by mild acidification in citrate buffer to dissociate any lig-
ands loosely-bound to mARs or iARs [13] and extensive
washing with TBS pH 7.4.
When slides were incubated with testosterone-BSA-FITC
without any treatment, they presented a high non-specific
binding (Figure 1, upper panel), due probably to the non-
specific absorption of BSA to membrane and/or intracel-
lular structures or molecules. For this reason, slides were
preincubated with a 3% BSA solution prior to ligand bind-
ing. As shown (Figure 2A and 2B) this treatment resulted
in an attenuation of conjugated or unconjugated BSA-
FITC to membranes.
Another matter of concern was that iARs, regularly present
in prostate carcinoma cells, could bind the ligand since, in
tissue sections, one expects an interaction of the conju-
gated ligand with membrane and (due to sectioning)
intracellular structures and/or molecules, including iARs.
Our previous results with prostate cancer cell lines have
shown that interaction of testosterone-BSA with mARs is
not influenced (at the level of binding or the resulting sig-BMC Cancer 2005, 5:148 http://www.biomedcentral.com/1471-2407/5/148
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naling cascade and secretion) by antiandrogens [6,9]
Therefore, to eliminate a possible interaction of BSA con-
jugated ligand with iARs, we used 10-4M cyproterone ace-
tate in the binding experiments.
This treatment decreased nuclear, membrane and intracel-
lular staining (Figure 1). The treatment of slides with tes-
tosterone-BSA-FITC in the presence of 3% BSA and 10-4M
cyproterone acetate decreased non-specific staining in
nearly background levels, making more discernible the
interaction of testosterone-BSA-FITC with specific mem-
brane-binding sites (compare Figure 1 with Figure 2A
right panel).
According to the above results, for the detection of mARs
in tissue sections, we applied BSA (3%) and cyproterone
acetate (10-4M) throughout the present study. These con-
ditions were found to accurately discriminate between
positive (>75% of cells labeled by testosterone-BSA-FITC)
and negative (<10% of cells labeled by testosterone-BSA-
FITC) cases.
2. Prostate carcinoma specimens preferentially express 
mARs
On examination of the specimens, positive cases of both
carcinomas and BPHs were found to present peripheral,
membrane type, fluorescence. In contrast, morphologi-
cally normal-looking prostate epithelial tissue showed no
specific fluorescence. In Figure 2, representative cases of
prostate carcinoma are presented, showing a positive (Fig-
ure 2A) or negative (Figure 2B) staining for mARs. Positive
cases showed peripheral, continuous and/or stippled,
membrane type, fluorescence. This extended over more
than 75% of carcinoma cells of the tissue section. Nega-
tive cases, on the other hand, showed no more than 10%
reacting cells. Intensity of staining in positive cells was not
considerably different among cases. Thus, reading and
translating mAR positivity seems to be a matter of nearly
a "black and white" effect and membrane pattern recogni-
tion.
The tissue stroma sometimes showed a diffuse positive
reaction, probably due to connective tissue non-specific
binding. This non-specific staining did not interfere,
though, with the estimation of mAR expression in epithe-
lial cells of the tissue section. Ninety percent (90%) of
BPHs were negative for mAR, while about 38% of carcino-
mas were positive (Figure 3) (χ2 = 23.24, p < 0.0001). No
correlation was found between mAR expression and age
of the patient, treatment before or after surgery and sur-
vival.
3. Membrane Androgen Receptor sites are related to the 
level of differentiation of prostate carcinoma
As mentioned above, 38% of prostate carcinomas were
found to express mARs (χ2 6.68, p < 0.1, among all cases
of carcinoma, n = 109). Thus, mAR expression cannot be
Prostate carcinoma staining with testosterone-BSA-FITC Figure 1
Prostate carcinoma staining with testosterone-BSA-FITC. Repre-
sentative patterns of prostate carcinoma tissue section stain-
ing with testosterone-BSA-FITC in absence of BSA and 
cyproterone acetate preincubation (upper panel) or in pres-
ence of cyproterone acetate and in absence of BSA (lower 
panel). As explained in the text, BSA preincubation decreases 
or eliminates non-specific interactions of the tracer (testo-
sterone-BSA-FITC) with prostate stroma or cell membranes, 
while the antiandrogen cyproterone acetate binds selectively 
to iAR.BMC Cancer 2005, 5:148 http://www.biomedcentral.com/1471-2407/5/148
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Representative cases of mAR positive (A) and negative (B) tumor specimens Figure 2
Representative cases of mAR positive (A) and negative (B) tumor specimens. A representative case of mAR positive (A) and a nega-
tive case (B) are shown. Left panels present H&E staining, middle panels present BSA-FITC staining, while right panels present 
staining with testosterone-BSA-FITC. Note the membrane localization of fluorescence in positive cells. Lower panel presents a 
higher magnification of the square region shown. In all cases preincubation with 3% BSA and 10-4M cyproterone acetate was 
performed, prior to mAR detection. Compare Figure 2 with Figure 1 (no preincubation).BMC Cancer 2005, 5:148 http://www.biomedcentral.com/1471-2407/5/148
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used for the discrimination between malignant and
benign prostate cases. To evaluate the possible role of
mARs in the evolution of prostate carcinoma, we corre-
lated the presence or absence of mARs to the differentia-
tion of the prostate carcinoma, estimating the Gleason's
sum of each case on the corresponding H&E stained slide.
Using correlation analysis, our results showed that mAR
expression is positively related to higher Gleason's sum
(Mann-Whitney U = 991, p < 0.04, Spearman's rho =
0.236, p < 0.01, Figure 4). It is worthy to note that 50% of
poorly differentiated carcinomas (Gleason's sum 8 and 9,
in our series) expressed mARs while in the Gleason's sum
9 carcinomas, mARs expression predominated. As seen in
Figure 4, there is an increased expression of mARs with
increasing Gleason's sum (15%, 40%, 44%, 36%, 71%,
for Gleason's sums from 5 to 9 respectively). No differ-
ence was found between Gleason's sum 4+3 and
Gleason's sum 3+4 regarding mAR expression (11 out of
21 cases of Gleason's sum 3+4, and 9 out of 20 cases of
Gleason's sum 4+3 expressed mAR).
Different percentages of mAR positivity were revealed
when prostate carcinoma cases were stratified according
to the type of tissue sample. The number and percentages
of positive carcinoma cases in each type of specimen is
presented in Table 2. Radical prostatectomies showed
13.04% positivity and transurethral resection specimens
showed 26.22%, while almost half of the transrectal biop-
sies were found to express mARs (47.80%). The number
of transrectal biopsies (68 studied) was higher correlated
to the number of cases of the other two groups (radical
prostatectomies 23 and transurethral resections 15). Sta-
tistical analysis showed that there is a significant differ-
ence in mAR expression between the three types of tissue
samples (binomial distribution comparison, p < 0.01).
Discussion
The classical mode of action of steroid hormones includes
their entrance into hormone-dependent cell and binding
to their intracellular cognitive receptors, which subse-
quently dimerize and translocate to the nucleus, acting as
specific transcription factors [14]. This sequence of events
requires time for their completion (>2 hours). In recent
years, however, steroids were found to exert a number of
effects in seconds or minutes, a phenomenon not
explained by their intracellular action. Ion mobilization,
activation of specific signaling cascades or secretion are
included among these rapid actions and are considered
non-genomic, independent of transcription or translation
[[15], see [16], for a review]. A number of possible expla-
nations for the non-genomic steroid actions include the
presence of membrane binding sites, different from intra-
cellular receptors [17], the anchorage of intracellular
receptors to the plasma membrane through post-transla-
tional modification of receptor molecules [18], the inter-
action of intracellular steroid receptors with other
membrane-bound receptors, or the activation of signaling
molecules through intracellular receptor-bound steroids.
Recently, a progesterone binding membrane site has been
isolated and found to belong to the seven-loop G-protein
coupled receptor superfamily [19]. Data on other steroids
binding membrane sites have also been reported [2,4,20-
22], although their molecular nature has not been eluci-
dated until now. More recently, we have reported the
identification of mARs in prostate cancer cell lines [5,6]
and in a small series of human prostate carcinomas [8].
Membrane androgen receptor sites activation induces
Ca2+ flux [23], actin reorganization [9] and PSA secretion
[5], in an antiandrogen-independent manner, inducing
apoptosis in vitro [6,7] and in vivo [6]. In addition, triti-
ated testosterone has been found to bind efficiently and
specifically to acid-stripped membranes [5].
The above data indicate that the detection of mARs could
be of value in the diagnosis; and possibly mARs them-
selves could be exploitable in a new therapeutic approach
of the mAR positive prostate carcinomas, as prostate carci-
noma xenografts in nude mice are significantly reduced in
size by testosterone-BSA treatment of animals [6]. In the
present study we investigated whether mARs could also be
detected in formalin-fixed and paraffin-embedded speci-
mens of prostate carcinoma. The main disadvantage in
mARs detection is that, until the elucidation of their
molecular structure, no antibodies interacting with them
are available. In addition, antibodies to iAR do not cross-
react with mAR [7]. Therefore, for the time being, the only
appropriate method for mAR detection is that based on
Distribution of positive and negative mARs in BPH and pros- tate carcinoma Figure 3
Distribution of positive and negative mARs in BPH and prostate 
carcinoma. Ninety % of benign prostate hyperplasia cases (n = 
103) were negative for mAR receptor expression. On the 
other hand, prostate carcinoma cases (n = 106) showed 
mAR expression in a significant percentage (38% of these 
cases were positive) (χ2 = 16.7, p < 0.0001).BMC Cancer 2005, 5:148 http://www.biomedcentral.com/1471-2407/5/148
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the use of labeled non permeable ligands, such as testo-
sterone-BSA-FITC. Previous results of experiments of our
team performed in formalin- or PFA-fixed cell lines
(LNCaP, DU-145, and PC12) and circulating leukemic
lymphocytes have shown that mAR could be effectively
detected on the cell surface. In view of these data, in the
present study we used mild deparaffinization, in combi-
nation with citrate buffer pretreatment, known to induce
dissociation of ligands or iAR loosely-bound on mem-
brane sites [7,13]. Our results indicate that, under such
conditions, mARs could be detected in prostate carcino-
mas on formalin-fixed and paraffin embedded tissue sec-
tions.
A problem encountered in our attempt to reveal in situ
mARs was that BSA-FITC bound non-specifically to/or it
was absorbed by stromal structures or cell and/or intracel-
lular components. In order to decrease this non-specific
interaction, we pre-incubated tissue sections on slides
with high concentrations of BSA, thus eliminating or effi-
ciently decreasing this interaction. Intracellular ARs (iARs)
do not interfere with the detection of mARs by the
method presented here. Indeed, as found in our previous
studies, these latter sites do not react with antiandrogens,
which can block intracellular receptors [6,9]. We have
therefore exploited this differential antiandrogen selectiv-
ity in order to block selectively iAR binding, by the use of
high concentrations of the antiandrogen cyproterone ace-
tate. In addition, we report that, although confocal micro-
scopy could be considered more precise and accurate than
the -cheaper in hardware- conventional fluorescence
microscopy, once the researcher becomes accustomed to
mAR expression pattern, conventional fluorescence
microscopy can be a valuable alternative in revealing the
presence of mAR in tissue sections.
Our findings indicate that intensity is not a factor to take
into account in the evaluation of mAR expression, since,
in individual positive cases, a rather uniform staining
intensity was observed. In the case of advanced prostate
carcinomas there is a heterogeneity of cell populations
expressing iAR [24,25], suggesting iAR counting in hot
spots. Such heterogeneity was not observed in our study
of mARs, and thus positivity was estimated in 10 sequen-
tial high power fields in representative tissue section
regions (X400).
The most appropriate samples for the study of mAR
expression seem to be the transrectal biopsies (50% posi-
tivity), which constituted most of our specimens (71 out
of 106 finally studied), followed by the TUR specimens
(26.66% positivity), and the radical prostatectomy speci-
mens (13.04% positivity). This signifies that the quality of
fixation (as depended on time and room temperature) is
of critical importance in the study of mARs.
We report that only 38% of prostate carcinoma cases are
positive for mAR staining. In this respect, mAR positivity
could not be a discriminant factor for prostate cancer diag-
nosis. Stratification of cases, according to the Gleason's
sum revealed that mAR-positive staining correlates with
less differentiated tumors. No significant difference in
mAR expression between Gleason's sum 4+3 (9 out of 20
cases) and Gleason's sum 3+4 (11 out of 21 cases) pros-
tate carcinomas was found. Nevertheless, no solid conclu-
sions can be drawn, due to the relatively small number of
cases studied.
Correlation of mAR positivity with Gleason's sum in prostate  carcinomas Figure 4
Correlation of mAR positivity with Gleason's sum in prostate carci-
nomas. Membrane androgen receptors are preferentially 
expressed in prostate carcinomas and their presence is cor-


























Table 2: Type of specimens and results of the study for mAR expression
Type of specimen Positive Negative Rejected Total % of positivity
Radical 
prostatectomy
3 20 0 23 13,04
Transurethral 
resection
4 11 0 15 26,66
Transrectal biopsy 34 34 3 71 50,00
Total 41 65 3 109 38,60BMC Cancer 2005, 5:148 http://www.biomedcentral.com/1471-2407/5/148
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Membrane androgen receptors are not only expressed in
the prostate. They have been found in osteoblasts, lym-
phoid cells and Sertoli cells [reviewed in [12]] independ-
ently of the presence or not of iARs. Preliminary data from
our group studies indicate that mARs are expressed in
higher grade carcinomas of the breast, B-lymphomas,
pheochromocytomas and in AC133+  cord blood stem
cells (unpublished observations). In addition, in estrogen
receptor negative (ER-negative) carcinomas of the breast
we have found a strong staining for mAR [7]. In this
respect, mAR might be considered rather as a marker of
"immature" and behaviorally aggressive cells than a tissue
specific marker. If this comes true, it could explain the
finding that tumors with high Gleason's sum preferen-
tially express mARs.
Conclusion
Our results indicate that mARs detection cannot discrimi-
nate between prostate carcinoma and BPH, not being
exploitable in the differentiation between low-grade carci-
nomas and BPHs. Nevertheless mARs could be used for a
biologic grading of prostate carcinomas, since the more
aggressive ones-of higher histopathological grade- prefer-
entially express mARs. Results of recent studies of our
team indicate that agonists of mARs-being expressed in
cases of both iAR-positive and iAR-negative prostate can-
cer cell lines-might act as specific therapeutics directing
carcinoma cells towards apoptosis [6]. In addition, the
activation of mAR-signaling cascade leads to apoptosis
[6], while activation of iARs is antiapoptotic [26]. This, in
combination with the finding that prostate carcinomas of
low Gleason score have a significantly higher iAR content
than those with high Gleason score [27], signifies a differ-
ent biological role for mARs in relation to iARs. Hence,
the possibility that combined examination of iARs and
mARs in prostate carcinomas, in the context of a test clin-
ically applicable and easy to perform, could lead to a more
accurate biologic grading of predictive and/or prognostic
importance. To test the prognostic power of mARs, further
studies in prostate carcinomas are needed. Moreover,
mARs' study in large series of prostate carcinomas is
imperative in order to fully elucidate the pathway of their
action and reveal whether they represent a possible target
for new therapies of these carcinomas, especially in view
of our results on regression of prostate tumor xenografts
by testosterone-BSA [6].
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